XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SHARE-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
Stock Options
The Company has issued non-qualified and incentive stock options to employees and non-employee directors. The fair values of these options were estimated on the grant dates using the Black-Scholes option pricing model, which required estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Company’s common stock, and dividend yield. Options outstanding as of June 30, 2024 generally vested over a period of 3 years and expire 10 years from the date of grant. The exercise price of these options is $66.68. Due to the Company’s lack of option exercise history on the date of grant, the expected term was calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk-free interest rate was based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponded to the expected term of the option. The expected volatility was based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. The dividend yield was computed as the annualized dividend rate at the grant date divided by the strike price of the stock option. For the six months ended June 30, 2024 and 2023, the Company did not grant stock options.
The following table is a summary of our stock option activity (in thousands, except per share data):
Six months ended June 30,
20242023
AwardsWeighted-Average Exercise PriceAwardsWeighted-Average Exercise Price
Outstanding at beginning of period26 $62.20 33 $54.98 
Exercised(1)27.68 (4)27.18 
Forfeited(2)26.52 — — 
Outstanding at end of the period23 $66.68 29 $58.65 
Exercisable at end of the period23 $66.68 29 $58.65 
As of June 30, 2024, the weighted-average remaining contractual life for both the outstanding stock options and exercisable stock options was 3.6 years with an aggregate intrinsic value of $0. There was no unrecognized compensation on the awards for the period ended June 30, 2024. For the six months ended June 30, 2024 and 2023, the Company received $36 thousand and $105 thousand in cash proceeds from the exercise of stock options, respectively. The total intrinsic value for stock options exercised during the six months ended June 30, 2024 and 2023 was $15 thousand and $328 thousand, respectively.
Restricted Stock
The Company has issued restricted stock to employees and non-employee directors generally with vesting terms up to 3 years after the date of grant. The fair value of the restricted stock is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period.
The following table summarizes our restricted stock activity (in thousands, except per share data):
Six months ended June 30,
20242023
SharesWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of period114 $127.87 60 $188.11 
Granted210 32.23 85 98.17 
Vested(34)138.80 (24)169.42 
Forfeited(4)52.06 (3)156.26 
Outstanding at end of the period286 $57.21 118 $127.93 
The Company withheld approximately 11 thousand shares and 9 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of restricted stock for the six months ended June 30, 2024 and 2023, respectively. The total fair value of restricted stock awards vested during the six months ended June 30, 2024 and 2023 was $1.3 million and $2.5 million, respectively.
Market and Performance-based Share Awards
The Company has issued market and performance-based share awards in 2022 and 2023 and performance-based share awards in 2020, 2021, and 2024 to certain key executives who were granted deferred shares and may earn between 0% and 250% of the target number depending upon both the Company’s total stockholder return (“TSR”), for those with market conditions, and the Company’s performance against predetermined performance goals over a three-year performance period after the date of grant. Market and performance-based share awards that are tied to the Company’s TSR are valued using the Monte Carlo method and are recognized ratably as expense over the award’s performance period. The fair value of the performance-based share awards is equal to the market price of the Company’s common stock on the date of grant adjusted by expected level of achievement over the performance period. Expense for performance-based share awards is amortized ratably over the performance period. In the event that management determines that the Company will not reach the lower threshold of the predetermined performance goals established in the grant agreement, any previously recognized expense is reversed in the period in which such a determination is made. Management determined that the market and performance-based share awards granted in March of 2022 and performance-based share awards granted in October of 2021 would not reach the lower threshold of the predetermined performance goals resulting in a $1.4 million and $0.1 million decrease in the Company’s share-based compensation expense during the three months ended March 31, 2023 and June 30, 2024 respectively.
The Company withheld 8 thousand shares and 21 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of performance-based share awards for the six months ended June 30, 2024 and 2023, respectively. The total fair value of performance-based share awards issued during the six months ended June 30, 2024 and 2023 was $1.3 million and $5.3 million, respectively.
Share-based compensation expense for all types of awards granted is recorded in selling, general, and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The total expense during the three months ended June 30, 2024 and 2023 was as follows (in thousands):
Three months ended June 30,
20242023
SharesShare-Based Compensation ExpenseSharesShare-Based Compensation Expense
Options and restricted stock309 $1,717 147 $1,642 
Performance-based share awards granted in 2024117 371 — — 
Market and performance-based share awards granted in 202347 482 47 482 
Market and performance-based share awards granted in 202224 — 24 — 
Performance-based share awards granted in 20211 (116)14 340 
Performance-based share awards granted in 2020— — 28 50 
Total share-based compensation498 $2,454 260 $2,514 
The total expense during the six months ended June 30, 2024 and 2023 was as follows (in thousands):
Six months ended June 30,
20242023
SharesShare-Based Compensation ExpenseSharesShare-Based Compensation Expense
Options and restricted stock309 $3,317 147 $2,869 
Performance-based share awards granted in 2024117 448 — — 
Market and performance-based share awards granted in 202347 964 47 561 
Market and performance-based share awards granted in 202224 — 24 (1,388)
Performance-based share awards granted in 20211 (104)14 980 
Performance-based share awards granted in 2020— — 28 98 
Total share-based compensation498 $4,625 260 $3,120 
The total income tax benefit recognized in the accompanying Condensed Consolidated Statements of Operations for stock awards was $0.1 million and $0.0 million for the three months ended June 30, 2024 and 2023, respectively, and the income tax expense of $0.4 million and income tax benefit of $0.1 million for the six months ended June 30, 2024 and 2023, respectively.

There was $10.7 million of total unrecognized compensation cost related to restricted stock awards as of June 30, 2024, which is expected to be recognized over a weighted-average period of 2.00 years. There was $6.6 million of unrecognized compensation costs related to the 71 thousand market and performance-based shares and 118 thousand performance-based shares presented in the table above as of June 30, 2024, which is expected to be recognized over a weighted-average period of 1.88 years.